Nurix Therapeutics (NRIX) Non-Current Deffered Revenue (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Non-Current Deffered Revenue data on file, last reported at $6.0 million in Q2 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 72.41% year-over-year to $6.0 million in Q2 2026; TTM through May 2026 was $6.0 million, a 72.41% decrease from a year earlier, with the FY2025 full-year figure at $10.0 million, down 61.8% from the prior year.
• Non-Current Deffered Revenue for Q2 2026 stood at $6.0 million, down from $7.6 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for NRIX reached as high as $55.4 million in Q1 2022 and fell as low as $6.0 million in Q2 2026.
• Historically, Non-Current Deffered Revenue has averaged $27.1 million across 5 years, with a median of $26.2 million in 2023.
• Across the five-year window, Non-Current Deffered Revenue sank 75.35% in 2023 and surged 191.5% in 2024, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $36.0 million in 2022, then increased by 25.15% to $45.0 million in 2023, then sank by 41.79% to $26.2 million in 2024, then sank by 61.8% to $10.0 million in 2025, then plunged by 40.36% to $6.0 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $6.0 million in Q2 2026, $7.6 million in Q1 2026, and $10.0 million in Q4 2025.